Industry
Celltrion posts record Q1 as new biosimilars drive earnings surge
SEOUL, May 06 (AJP) - South Korean biopharmaceutical firm Celltrion reported its strongest first-quarter results on record, as a wave of newly launched biosimilars accelerated overseas sales and pushed operating profit more than twofold higher. According to regulatory filings released Wednesday, the company logged consolidated revenue of 1.14 trillion won ($779.43 million) and operating profit of 321.9 billion won for the three months ended March 31, up 36 percent and 115.5 percent,
May 6, 2026
-
Hanwha Aerospace increases Korea Aerospace Industries stake to pursue management role May 5, 2026
-
Samsung Elec changes TV chief as Chinese rivals ascend May 4, 2026
-
Korean shipbuilders draw 6 orders for very large carriers amid Hormuz disruption May 4, 2026
-
Korea University, UNIST team up to build Korean version of Harvard-MIT HST May 4, 2026
-
Samsung family completes $9 bn inheritance tax payment as AI boom reshapes empire May 3, 2026
-
Samsung's AI chip bonanza fuels bitter divide inside Korea's biggest company May 3, 2026
-
Soaring fuel surcharges push up overseas travel costs amid Iran war May 2, 2026
-
Trump's Germany troop cut, EU tariff hike fuel concerns in Seoul May 2, 2026
-
Krafton's Unknown Worlds sets May 14 early access launch for Subnautica 2 May 1, 2026
